ADL5945: Phase II started

Adolor began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily 0.1 and 0.25 mg ADL5945 over 4 weeks in 120 patients. Adolor has exclusive, worldwide rights to develop and...